|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
| Lutetium-177 PSMA Radioligand Therapy for Advanced Prostate Cancer: Reviewing the Pivotal VISION and TheraP Trials |
Michael Morris, MD
Daniel George hosts Michael Morris to discuss pivotal studies influencing the use of lutetium PSMA-617 in treating prostate cancer. The conversation begins with the VISION study, which led to Pluvicto's approval by demonstrating significant improvements in radiographic progression-free survival and overall survival for patients with PSMA-positive disease. |
|
|
|
|
|
|
|
|
|
|
| Clinical Considerations for Patient Selection for Lutetium-177 PSMA |
Gordon Brown, DO
Gordon Brown delves into the clinical considerations of integrating PLUVICTO into urology practices. Dr. Brown explains the role of Summit Health's navigation team in identifying and monitoring patients for advanced prostate cancer therapies. |
|
|
|
|
|
|
|
|
|
|
|
Exploring PSMA PET-Based Response's Prognostic Role in Prostate Cancer Treatment - Journal Club
|
Rashid Sayyid, MD, MSc, and Zachary Klaassen, MD, MSc
Rashid Sayyid and Zach Klaassen discuss a Journal of Nuclear Medicine publication titled, “The Prognostic Role of 68Ga-PSMA11 PET-Based Response in Prostate Cancer Patients Undergoing Taxane-Based Chemotherapy.”
|
|
|
|
|
|
|
|
|
|
|
| PSMA PET Standardized Reporting "Presentation" |
| Matthias Eiber, MD, Ph.D. |
| At the 2024 UCSF-UCLA PSMA Conference, Matthias Eiber advocates for standardized reporting in PSMA PET imaging, underscoring its significance in improving clinical and research communication, with frameworks like PROMISE, PSMA-RADS, PPP, and RECIP enhancing treatment decision-making and lesion assessment. |
|
|
|
|
|
|
|
|
|
|
|
| PSMA Radioligand Therapy: The VISION and TheraP Trials
|
| Michael Morris, MD
|
| Michael Morris presented findings from the VISION and TheraP trials at the 2024 PSMA conference. In the VISION trial, 177Lu-PSMA-617 demonstrated significant improvements in overall survival and radiographic progression-free survival compared to standard of care alone in men with PSMA-positive metastatic castration-resistant prostate cancer.
|
|
|
|
|
|
| 3TMPO: Prognostic Value of FDG, PSMA, and DOTATATE Uptake on PET Imaging in mCRPC |
| Frederic Pouliot, MD, Ph.D. |
| Frederic Pouliot presents findings from the 3TMPO study focusing on the prognostic value of FDG, PSMA, and DOTATATE uptake on PET imaging in metastatic castration-resistant prostate cancer (mCRPC). The study found that patients with FDG+/PSMA- lesions had significantly shorter overall survival compared to those without such lesions, and the prognosis was worse if they also had DOTATATE+ lesions. |
|
|
|
|
|
|
|
|
|
|
| Association Between PET-Based TheraP Eligibility and 177Lu-PSMA-617 Outcomes in VISION-Eligible Patients with mCRPC |
| Ridvan Arda Demirci, MD |
| Ridvan Demirci presents findings from a retrospective cohort study exploring the association between PET-based TheraP eligibility and outcomes in VISION-eligible patients with mCRPC treated with 177Lu-PSMA-617. The study revealed that patients deemed TheraP-ineligible had lower PSA response rates compared to TheraP-eligible patients but showed no significant difference in PSA-progression-free survival or overall survival. |
|
|
|
|
|
| What Are the Best Predictive Factors for Successful Treatment with Lu PSMA? |
| Stefano Fanti, MD |
| Stefano Fanti discusses predictive factors for successful treatment with LuPSMA in mCRPC. He highlights the challenge of non-responders in LuPSMA therapy and emphasizes the importance of treating what can be seen on PSMA-PET/CT scans. Current eligibility criteria for LuPSMA therapy include PSMA uptake above the liver and absence of PSMA-negative lesions, while predictive factors for response include high whole-body SUVmean, homogenous target expression, and low whole-body tumor volume. |
|
|
|
|
|
| The Role of PSMA PET in CRPC Patients |
| Wolfgang Fendler, MD |
| Wolfgang Fendler discusses the role of PSMA PET in patients with CRPC. He highlighted the importance of PSMA PET in accurately detecting metastases, leading to a considerable upshift in staging and volume assessment. PSMA PET accurately stratifies subgroups of uni-, oligo-, or disseminated metastatic CRPC, allowing for quantification of total PSMA tumor volume. Dr. Fendler also emphasized the prognostic value of PSMA PET in predicting overall survival and its role as a gatekeeper for PSMA radioligand therapy. |
|
|
|
|
|
|
